In part 3 of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the hurdle of trying to reverse arteriosclerosis.

In this week's Homerun Slides, a look at empagliflozin and the effects of SGLT-2 inhibitors.

Cause of NAFLD: obesity and abnormalities in adipose tissue. Although both NAFLD and the MetS can occur in nonobese subjects, the prevalence of NAFLD is markedly increased in obesity as is that of the MetS. In the third National Health and Nutrition Examination Survey (NHANES), the prevalence of NAFLD averaged 7.5% and 6.7% in normal-weight men and women but was 57 and 44% in persons with a body mass index (BMI) greater than 35 kgm−2.

We lost one of our first board members last week when Dr. Keith Campbell, Pharmacist, CDE, Professor of Pharmacy at Washington State, passed away at the age of 76. Keith had recently been bestowed the Lifetime Achievement Award from Washington State University. Keith will be missed by the thousands of …

Research presented at the American Heart Association provided new insight into  two large diabetes drug trials, CANVAS and EMPA-REG OUTCOME.

CGM will be available at lower price, without fingerstick calibration, and can be worn for 10 days with 12-hour warmup.

HbA1c, daily insulin dose requirement also found to benefit from treatment.

Diet may play a major role in magnesium and its association to type 2 diabetes.

Researchers found that the Alzheimer’s gene ApoE4 could be linked to type 3 diabetes. The Apolipoprotein E (APOE) gene is one of the strongest genetic risk factors for Alzheimer’s disease. Diabetes and impaired insulin signaling in the brain are linked to the development of Alzheimer’s disease. This study shows how …

A 64-year-old female presents to your office for her 3-month follow-up. She has previously been diagnosed with mild diastolic heart failure, secondary to hypertension. She currently takes an ace-inhibitor and a diuretic with good control of her heart failure symptoms and hypertension. At her last visit, she had a FPG 118 mg/dl. In a subsequent conversation with her, you discussed how she has developed prediabetes and suggested lifestyle modifications. Since her last visit, she has taken up very gentle walking four times/week and has changed her diet to a more healthful one. Despite these positive changes, this visit’s labs return an A1C 7.8%; her remaining labs are within normal limits. Which one of the following antihyperglycemic medication classes would you choose to initiate treatment? A. Sulfonylureas B. Biguanides C. Insulin D. Thiazolidinediones Follow the link for the answer.